News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

A three-drug combination targeting aggressive advanced breast cancer could potentially ... protein – as well as the hormone ...

Mei Wei, MD, an oncologist specializing in breast ... CDK4/6 inhibitors plus aromatase inhibitors as the first line of therapy has significantly improved the PFS and the overall survival as ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

A three-drug combination targeting aggressive advanced breast cancer could ... alongside the hormone therapy fulvestrant as ...

Hormone therapy (also called ... women with low-risk breast cancer who (by patient choice and physician recommendation) did not receive chemotherapy, 12-year survival is excellent regardless ...

Rifampin, phenytoin and carbamazepine should be avoided with ribociclib therapy ... improves survival in post-menopausal women with hormone receptor-positive metastatic breast cancer.

New treatments — along with others being evaluated — are game changers in terms of survival. Chen cites Ribociclib, a drug used for many years for those with metastatic breast cancer.

Huge breakthrough’ in breast cancer drug therapy ‘doubles survival time’ - New three drug combination could be ...